India Cdsco Medical Device Registration Service

Start with the filing route, not the dossier

For a medical device that requires an Indian import licence, the operational filing route is an application in Form MD-14 by the Indian authorised agent to the Central Licensing Authority through the CDSCO online system; the licence, if granted, is issued in Form MD-15. The first execution decision is therefore not “which documents do we upload?” but “does this device actually belong on the MD-14/MD-15 route?”

This page owns the filing execution task. If the unresolved issue is classification strategy, regulatory pathway selection or a pre-filing gap assessment, use the India CDSCO medical device registration consultant page. For a country-wide map of unrelated Indian product-compliance regimes, use the product compliance and market access services in India hub.

Who files, and what must be fixed before submission

Rule 34 places the application with an authorised agent in India that holds the qualifying sale/distribution/manufacturing basis required by the Medical Devices Rules and the current CDSCO checklist. The current MD-14 checklist also recognises the relevant wholesale/manufacturing licence or Form MD-42 registration certificate, as applicable. For an overseas manufacturer, the authorised-agent relationship is evidenced through a Power of Attorney and the agent’s undertaking.

Before drafting MD-14, freeze a single “registration dataset” for names, addresses, device identifiers, intended use, risk class, grouping and site. The CDSCO specimen MD-14 explicitly expects these fields to align with the Device Master File, IFU/user manual/package insert and labels.

Build the dossier as a controlled evidence set

The fresh-application checklist and the Fourth Schedule show that the filing is not a single form. It is a controlled package that ties the applicant, overseas manufacturer, manufacturing site and each device to supporting evidence.

• Applicant and authority documents: covering letter, MD-14, fee challan, Power of Attorney with authorised-agent undertaking, evidence of the agent’s eligible licence/registration and constitution details.
• Regulatory status: overseas manufacturing-site/establishment registration and Free Sale Certificate or marketing authorisation where applicable, together with other recognised market authorisations where relied upon.
• Quality system: QMS/full quality assurance/production quality assurance evidence for the actual manufacturing site and, where available/applicable, the latest inspection or audit report.
• Site file: Plant/Site Master File in the structure required by Appendix I of the Fourth Schedule.
• Device file: Device Master File in Appendix II format for non-IVD devices, including device description, specifications and variants, grouping justification, labelling, design/manufacturing information, Essential Principles evidence, risk analysis, verification/validation and applicable biocompatibility, sterilisation, software, stability, clinical and post-market evidence.

Dossier consistency check before upload

Submission workflow: from dossier freeze to MD-15

1. Confirm the route. Verify that the device is regulated, confirm its CDSCO risk class and check whether the Class A non-sterile/non-measuring exemption changes the filing path.
2. Fix the applicant and scope. Confirm the authorised agent, manufacturer, manufacturing site, device list and application grouping.
3. Map existing evidence. Compare the manufacturer’s current technical file against the Fourth Schedule and the latest CDSCO checklist rather than merely renaming foreign documents.
4. Close documentary gaps. Prepare the POA/undertaking, regulatory and QMS certificates, PMF, DMF, labels/IFU and any missing validation or clinical evidence required by the chosen route.
5. Prepare MD-14 and fee evidence. Populate the form from the frozen registration dataset. The Second Schedule sets site- and device-based fees for import-licence applications; confirm the currently applicable amount before payment.
6. Submit online. The authorised agent files through the CDSCO online system and preserves the submitted version, payment proof and portal acknowledgement.
7. Control authority queries. Treat every clarification response as a dossier amendment: answer the question, identify changed documents, maintain version control and ensure no response creates a contradiction elsewhere.
8. Verify the issued licence. When MD-15 is granted, reconcile the licensed manufacturer/site/device details against the intended commercial portfolio before first shipment.

The Medical Devices Rules state that the Central Licensing Authority may grant MD-15 or reject the application, with reasons recorded in writing, within nine months from the date of application. This is a statutory rule, not a promise that every file will be commercially cleared in a fixed number of months; inspection, deficient evidence, route-specific requirements or authority questions can affect execution.

Decision points that can change the filing burden

A safe filing service should identify route-changing facts before upload. Under Rule 36, the prior-market and country-of-origin evidence can affect the clinical-evidence path. A Free Sale Certificate from Australia, Canada, Japan, EU countries or the United States is specifically addressed in the rule; devices from other countries can face different evidence conditions depending on class. This should be tested against the exact device facts, not reduced to a generic “CE/FDA approved = automatic India approval” assumption.

The Central Licensing Authority may also cause an overseas manufacturing-site inspection and, where it has reason to believe device quality is compromised, may require evaluation, testing or examination. These are authority powers, not steps that should be advertised as mandatory for every application.

Common rejection and delay triggers in an execution file

Many filing problems are not caused by the absence of a large technical report. They arise because the evidence set does not describe one coherent regulatory object. Before submission, run a hostile consistency review for:

• different spellings or addresses for the legal manufacturer, actual manufacturing site or authorised agent;
• models present on labels or certificates but missing from MD-14, or vice versa;
• intended-use wording that changes materially between MD-14, IFU and technical evidence;
• unsupported grouping of variants, accessories or systems;
• risk class that is asserted without checking the current CDSCO classification source;
• expired, non-authenticated or incorrectly legalised/apostilled supporting documents where authentication is required;
• QMS or Free Sale evidence tied to a different site/entity than the application;
• technical summaries that claim validation while the underlying report is missing, obsolete or scoped to another model;
• authority-query responses uploaded without updating affected dossier sections, creating a second version of the product story.

The objective is not to “make the portal accept files”; it is to make every filed item resolve to the same manufacturer, site, device, intended use, class and evidence chain.

Fees, licence maintenance and post-filing control

For non-IVD import licences, the consolidated Medical Devices Rules currently show a site fee plus a fee for each distinct device: Class A — USD 1,000 per site and USD 50 per distinct device; Class B — USD 2,000 per site and USD 1,000 per distinct device; Class C or D — USD 3,000 per site and USD 1,500 per distinct device. These figures apply to the MD-14 import-licence route and should not be applied to Class A non-sterile/non-measuring devices that instead use the mandatory registration route under the Class A exemption. Fees should be rechecked against the current Second Schedule immediately before payment.

An MD-15 licence remains valid in perpetuity unless cancelled or surrendered, subject to payment of the prescribed retention fee for each overseas manufacturing site and licensed device after every five years. The current CDSCO retention checklist also expects the licence history, endorsed devices, fee breakdown, statements on changes, QMS/regulatory evidence and recent post-market surveillance information.

Post-approval control is part of the filing service, not an afterthought. Rule 38 requires prompt handling of regulatory actions and distinguishes major and minor changes: prior approval is required before a major change specified in the Sixth Schedule, while minor changes are to be reported within the prescribed period. Changes to the constitution of the overseas manufacturer or authorised agent also trigger notification duties. Therefore maintain a change log linking every commercial, labelling, site, QMS and device change to its regulatory assessment before implementation.

What an execution-focused registration service should deliver

For this page’s filing-execution scope, the useful deliverable is not a generic regulatory memo. It is a submission package that can be filed, defended and maintained. A complete engagement normally separates the work into: route confirmation; authorised-agent/applicant readiness; dossier gap map; controlled MD-14 dataset; PMF/DMF assembly; document authentication check; fee and portal package; submission; query-response control; licence verification; and post-approval change/retention calendar.

What cannot be concluded without the actual device file should stay explicit. A service provider should not guarantee classification, clinical-investigation exemption, acceptance of a grouping, absence of inspection, approval or a fixed completion date until the product, origin, existing approvals, manufacturing site and evidence package are reviewed.

Official sources used for the filing framework

• CDSCO — Medical Device & Diagnostics
• Medical Devices Rules, 2017 — CDSCO consolidated copy
• CDSCO checklist for MD-14 / MD-15 import-licence filings
• CDSCO specimen Form MD-14
• CDSCO FAQ on Medical Devices Rules, 2017